Asthma Clinical Trial
Official title:
Exhaled Breath Condensates ("EBC") Study: Research Plan NIH/NIAID: Inner City Asthma Consortium (ICAC)
Current methods of measuring asthma severity can be problematic when used with children. A
measurement called exhaled breath condensates (EBC) may be a more useful way to determine
asthma severity in childhood. The purpose of this study is to determine if EBC measurements
are useful for determining asthma severity in asthmatic children as compared to currently
used laboratory measures.
Study hypotheses: 1) A broad panel of EBC measures will distinguish asthmatic children not
on inhaled corticosteroids (ICS) from both asthmatic children routinely taking ICS and
nonasthmatic controls. 2) Standardized equipment and methodologies for EBC collection,
processing, storage, shipping, and pH and mediator measurements can be developed that will
eliminate significant contamination from oropharyngeal saliva and allow for shipping and
processing at a central site.
The current national guidelines for assessing asthma severity have several limitations for
use in asthmatic children. One major limitation is that spirometric measures of airflow
limitation, including forced expiratory volume in one second (FEV1), generally cannot be
reliably obtained in children less than 7 years of age. Furthermore, most children with
asthma have essentially normal measures of airflow by spirometry or peak flow, so such
measurements are generally not useful in diagnosis and treatment. Previous studies indicate
that lung-specific biomarkers of inflammation, such as bronchial hyperresponsiveness
measures, might simplify, improve, and optimize the guidelines. Collection of EBC samples
may also be useful; EBC samples can be obtained by noninvasive means and are easier to
obtain than conventional samples. However, contamination by saliva is an issue in collecting
EBC samples, and standardization of sample collection is needed. This study will compare the
utility of two different sample collecting equipment, the EcoScreen and the R-Tube. This
study will also evaluate the usefulness of EBC samples in distinguishing between asthmatic
children taking ICS, asthmatic children not taking ICS, and nonasthmatic children.
There are 2 parts to this study. In Part A, two EBC samples will be collected from each
participant. Some participants will be have one EBC sample taken by the EcoScreen and the
other taken by the R-Tube; other participants will have both samples taken by the R-Tube. In
Part B, asthmatics taking ICS, asthmatics not taking ICS, and nonasthmatics will give 2 EBC
samples each via the R-Tube.
Participants will be asked to complete a questionnaire on their asthma symptoms and
allergies and will have a brief physical exam. Allergy skin prick testing, urine collection,
measurement of exhaled nitric oxide, and conventional incentive spirometry (used to obtain
several measures of lung function) will also occur. Participants will also be asked to
donate a blood sample.
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|